BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yaribeygi H, Ashrafizadeh M, Henney NC, Sathyapalan T, Jamialahmadi T, Sahebkar A. Neuromodulatory effects of anti-diabetes medications: A mechanistic review. Pharmacol Res 2020;152:104611. [PMID: 31863868 DOI: 10.1016/j.phrs.2019.104611] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Yaribeygi H, Maleki M, Butler AE, Jamialahmadi T, Sahebkar A. New insights into cellular links between sodium-glucose cotransporter-2 inhibitors and ketogenesis. J Cell Biochem 2022. [PMID: 36153819 DOI: 10.1002/jcb.30327] [Reference Citation Analysis]
2 Fan M, Yang W, He M, Li Y, Peng Z, Wang G. Occurrence, synthesis and biological activity of 2-(2-phenyethyl)chromones. European Journal of Medicinal Chemistry 2022;237:114397. [DOI: 10.1016/j.ejmech.2022.114397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Wium-andersen IK, Osler M, Jørgensen MB, Rungby J, Wium-andersen MK. Diabetes, antidiabetic medications and risk of depression – a population-based cohort and nested case-control study. Psychoneuroendocrinology 2022. [DOI: 10.1016/j.psyneuen.2022.105715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ashrafizadeh M, Kumar A, Aref AR, Zarrabi A, Mostafavi E. Exosomes as Promising Nanostructures in Diabetes Mellitus: From Insulin Sensitivity to Ameliorating Diabetic Complications. IJN 2022;Volume 17:1229-53. [DOI: 10.2147/ijn.s350250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Akbari A, Rafiee M, Sathyapalan T, Sahebkar A, Infante M. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis. Journal of Diabetes Research 2022;2022:1-17. [DOI: 10.1155/2022/7520632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Arbo BD, Schimith LE, Goulart dos Santos M, Hort MA. Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174800] [Reference Citation Analysis]
7 Yaribeygi H, Maleki M, Butler AE, Jamialahmadi T, Sahebkar A. The Impact of Incretin-Based Medications on Lipid Metabolism. J Diabetes Res 2021;2021:1815178. [PMID: 35005028 DOI: 10.1155/2021/1815178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wu K, Liu H, Zheng J, Zou L, Gu S, Zhou R, Yuan Z, Huang Z, Wu X. Diabetes Treatment Is Associated With Better Cognitive Function: The Age Disparity. Front Aging Neurosci 2022;13:753129. [DOI: 10.3389/fnagi.2021.753129] [Reference Citation Analysis]
9 Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, Jalali M, Atkin SL, Al-Rasadi K, Jamialahmadi T, Sahebkar A. GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:8936865. [PMID: 34805029 DOI: 10.1155/2021/8936865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Yaribeygi H, Farrokhi FR, Abdalla MA, Sathyapalan T, Banach M, Jamialahmadi T, Sahebkar A. The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes. J Diabetes Res 2021;2021:6518221. [PMID: 34258291 DOI: 10.1155/2021/6518221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Radbakhsh S, Atkin SL, Simental-Mendia LE, Sahebkar A. The role of incretins and incretin-based drugs in autoimmune diseases. Int Immunopharmacol 2021;98:107845. [PMID: 34126341 DOI: 10.1016/j.intimp.2021.107845] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
12 Stanciu GD, Rusu RN, Bild V, Filipiuc LE, Tamba BI, Ababei DC. Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer's Disease and Diabetes. Biomedicines 2021;9:576. [PMID: 34069618 DOI: 10.3390/biomedicines9050576] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
13 Ramaholimihaso T, Bouazzaoui F, Kaladjian A. Curcumin in Depression: Potential Mechanisms of Action and Current Evidence-A Narrative Review. Front Psychiatry 2020;11:572533. [PMID: 33329109 DOI: 10.3389/fpsyt.2020.572533] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
14 Hanchard J, Capó-Vélez CM, Deusch K, Lidington D, Bolz SS. Stabilizing Cellular Barriers: Raising the Shields Against COVID-19. Front Endocrinol (Lausanne) 2020;11:583006. [PMID: 33101215 DOI: 10.3389/fendo.2020.583006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Woo YS, Lim HK, Wang SM, Bahk WM. Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review. Int J Mol Sci 2020;21:E6969. [PMID: 32971941 DOI: 10.3390/ijms21186969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Pilipenko V, Narbute K, Pupure J, Langrate IK, Muceniece R, Kluša V. Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer's disease. European Journal of Pharmacology 2020;881:173290. [DOI: 10.1016/j.ejphar.2020.173290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]